DAILYPEPTIDE GUIDE
Approved Therapeutic

Tesamorelin

Egrifta · TH9507

Tesamorelin is an approved peptide-based therapeutic or diagnostic asset. Product-specific labels define its validated uses and risks.

Compare
EvidenceTier 1
RegulatoryApproved
SafetyKnown but Manageable Risks
Clinical phaseApproved
01

Overview

ClassGrowth hormone-releasing factor analogue
Sponsor / developerTheratechnologies
Review statusReviewed
Record IDPEP-016
02

Plain-language guide

What it was designed or studied for

Designed and approved for specific uses that include Excess abdominal fat in adults with HIV-associated lipodystrophy.

How it works, simply

It signals the pituitary gland to release more of the body’s own growth hormone. A hormone change alone does not prove muscle or recovery benefit.

This simplified explanation is educational context, not a treatment recommendation or a substitute for the clinical evidence below.
03

Clinical mechanism

Activates growth hormone-releasing hormone receptors to increase endogenous growth-hormone signaling.

Mechanism plausibility is not the same as demonstrated clinical benefit.
04

Applications

  • Excess abdominal fat in adults with HIV-associated lipodystrophy
05

Human evidence

Multiple human studies and regulatory review support at least one product-specific indication.

Tier 1
06

Preclinical evidence

Mechanistic and preclinical findings are tracked separately and are not treated as proof of human clinical benefit.

MAP

Muscle & recovery profile

Each signal is scored independently from 0–5. There is no composite “best” score.

Growth relevance1/5
Preservation relevance2/5
Recovery relevance1/5
Mitochondrial support0/5
Connective tissue1/5
Human-data depth4/5
Safety confidence3/5
Evidence–hype gap2/5

Evidence classes

  • Phase 3 / randomized human evidence

What has been studied

  • Body-composition outcomes have been studied for its approved, population-specific indication.

What is not established

  • Approved evidence does not establish general-purpose muscle gain, athletic enhancement or recovery.

Studied populations

  • Adults with HIV-associated lipodystrophy and excess abdominal fat

Major limitations

  • Muscle-specific outcomes may be secondary, exploratory or absent from available studies.
  • Findings from one population, formulation or indication should not be generalized to another.

Evidence-source categories: primary regulatory record, clinical trial registry, peer reviewed literature. These editorial source categories require record-level primary links before publication-grade citation export.

06

Regulatory status

Approved. Regulatory status is product- and jurisdiction-specific and does not automatically follow from an evidence score.

07

Safety

Known but Manageable Risks

  • Adverse effects vary by product and indication
  • Contraindications and interactions require label review
08

Interactions

Review the current product label and indication-specific literature for pharmacologic and absorption interactions.

09

Treatment pattern

Treatment patterns are product-, indication- and clinician-specific; this educational profile does not provide dosing guidance.

10

Manufacturing and quality

Approved-product identity, formulation and quality controls must not be extrapolated to compounded or RUO copies.

12

Sources

  1. 01
    Primary regulatory record

    Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.

  2. 02
    Clinical trial registry

    Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.

  3. 03
    Peer-reviewed literature

    Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.

13

Gaps and unverified claims

  • Evidence must be interpreted by indication and product label.
  • Approval does not establish safety or efficacy for off-label or compounded copies.
14

Last reviewed

August 5, 2026 · Reviewed